{"filing":{"accession_number":"0001193125-26-425684","cik":"0001882782","ticker":"ODTX","company_name":"Odyssey Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"odtx-20261020.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-20261020.htm"},"events":[{"id":36252,"run_id":33415,"accession_number":"0001193125-26-425684","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Odyssey Therapeutics disclosed completed Phase 2a clinical trial results for OD-001, its lead candidate for ulcerative colitis, presented at UEG Week 2026. The disclosure highlights positive efficacy data (primary endpoint met with p\u003c0.001), favorable safety profile, and mechanistic evidence supporting continued development into Phase 2b and Phase 2a combination trials. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the company's pipeline progress and probability of success, though it does not fit neatly into earnings, M\u0026A, governance, or financial obligation categories—making it an operational/strategic milestone best classified as operational_other.","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40599,"accession_number":"0001193125-26-425684","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Odyssey Therapeutics disclosed completed Phase 2a clinical trial results for OD-001, its lead candidate for ulcerative colitis, presented at UEG Week 2026. The disclosure highlights positive efficacy data (primary endpoint met with p\u003c0.001), favorable safety profile, and mechanistic evidence supporting continued development into Phase 2b and Phase 2a combination trials. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the company's pipeline progress and probability of success, though it does not fit neatly into earnings, M\u0026A, governance, or financial obligation categories—making it an operational/strategic milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:01:55.758681+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40599,"accession_number":"0001193125-26-425684","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Odyssey Therapeutics disclosed completed Phase 2a clinical trial results for OD-001, its lead candidate for ulcerative colitis, presented at UEG Week 2026. The disclosure highlights positive efficacy data (primary endpoint met with p\u003c0.001), favorable safety profile, and mechanistic evidence supporting continued development into Phase 2b and Phase 2a combination trials. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the company's pipeline progress and probability of success, though it does not fit neatly into earnings, M\u0026A, governance, or financial obligation categories—making it an operational/strategic milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:01:55.758681+00:00","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-10-20"}]}